TVTX sube un 13,91% por la optimismo de la FDA y las subvenciones estratégicas de RSU: ¿Un avance en biotecnología en el horizonte?

Summary
• Travere Therapeutics (TVTX) surges 16.33% amid FDA optimism for Filspari’s regulatory path
• Stock hits 52-week high of $42.13, driven by Cantor Fitzgerald’s positive analysis on proteinuria endpoints
• Q3 2025 earnings beat estimates with $0.28 EPS vs. -$0.31 consensus and $164.86M revenue
Travere Therapeutics (TVTX) is experiencing a historic intraday rally, surging 13.91% to $40.28 as of 19:46 EST. The stock’s meteoric rise is fueled by a confluence of catalysts: favorable FDA messaging on Filspari’s regulatory pathway, strategic RSU grants to attract talent, and robust Q3 financials. With the stock trading near its 52-week high, investors are weighing the sustainability of this momentum against mixed sector dynamics and insider selling.

FDA Flexibility on Proteinuria Endpoints Ignites TVTX’s Bullish Surge
Travere Therapeutics’ 13.91% intraday surge is directly tied to Cantor Fitzgerald’s analysis highlighting the FDA’s evolving stance on proteinuria reduction as an approvable endpoint for Filspari in focal segmental glomerulosclerosis (FSGS). The research firm noted the FDA’s flexibility in accepting either a responder analysis or percentage change in proteinuria at two years as sufficient for full approval. This regulatory optimism, combined with Dimerix’s prior suggestion of accelerated approval based on 52-week data, has galvanized investor sentiment. Additionally, the company’s Q3 earnings beat—$0.28 EPS vs. -$0.31 consensus and $164.86M revenue—provided further validation of its financial resilience, amplifying the stock’s upward trajectory.

Biotech Sector Volatility Intensifies as AMGN Gains 0.745%
The biotech sector remains a mixed bag, with Travere Therapeutics’ 13.91% surge starkly contrasting Amgen (AMGN)’s modest 0.745% intraday gain. While AMGN’s performance reflects broader market caution, TVTX’s rally underscores the sector’s susceptibility to regulatory and clinical catalysts. Cantor Fitzgerald’s positive FDA assessment for Filspari has positioned TVTX as a short-term outperformer, leveraging its niche focus on rare kidney diseases. However, insider selling—such as CEO Eric Dube’s 6.08% stake reduction—introduces caution, highlighting the sector’s inherent volatility.

Options and ETF Playbook: Capitalizing on TVTX’s Bullish Momentum
• 200-day average: 22.086 (well below current price)
• RSI: 52.67 (neutral, suggesting potential for further upside)
• MACD: 0.527 (bullish divergence with signal line at 0.637)
• Bollinger Bands: Price at $40.28 exceeds upper band of $36.47, indicating overbought conditions
• Kline pattern: Short-term and long-term bullish trends align
TVTX’s technicals paint a compelling case for continuation of the rally. Key levels to monitor include the 52-week high of $42.13 and the 200-day moving average at $22.086. With RSI in neutral territory and MACD showing bullish divergence, the stock is primed for a test of its upper Bollinger Band. The Kline pattern’s dual bullish signals reinforce this outlook. While no leveraged ETF data is available, the stock’s intrinsic momentum suggests a focus on options strategies.
Top Option 1: TVTX20260116C40
• Contract Code: TVTX20260116C40
• Type: Call
• Strike Price: $40
• Expiration Date: 2026-01-16
• IV Ratio: 92.94% (high volatility)
• Leverage Ratio: 10.07% (moderate)
• Delta: 0.5635 (moderate sensitivity)
• Theta: -0.1113 (rapid time decay)
• Gamma: 0.0410 (high sensitivity to price changes)
• Turnover: 64,042 (high liquidity)
Why it stands out: This call option offers a balance of leverage and liquidity, ideal for capitalizing on TVTX’s near-term upside. With a 5% upside projection (to $42.30), the payoff would be $2.30 per share, translating to a 57% return on the option’s premium. The high gamma ensures responsiveness to price swings, while the moderate delta mitigates overexposure.
Top Option 2: TVTX20260116C42.5
• Contract Code: TVTX20260116C42.5
• Type: Call
• Strike Price: $42.50
• Expiration Date: 2026-01-16
• IV Ratio: 108.57% (extremely high volatility)
• Leverage Ratio: 11.19% (high)
• Delta: 0.4826 (moderate sensitivity)
• Theta: -0.1207 (rapid time decay)
• Gamma: 0.0355 (moderate sensitivity)
• Turnover: 132,925 (exceptional liquidity)
Why it stands out: This contract’s high leverage and liquidity make it a top pick for aggressive bulls. A 5% upside (to $42.30) would yield a $0.20 payoff, a 180% return on the premium. The high IV ratio reflects strong market expectations, while the moderate delta ensures manageable risk. Aggressive bulls may consider TVTX20260116C42.5 into a breakout above $42.13.

Backtest Travere Therapeutics Stock Performance
The backtest of TVTX's performance after a 14% intraday increase from 2022 to now shows favorable results. The 3-Day win rate is 50.63%, the 10-Day win rate is 52.08%, and the 30-Day win rate is 52.92%, indicating that the ETF tends to experience positive returns in the short term following the intraday surge. The maximum return during the backtest was 7.98% over 30 days, suggesting that there is potential for significant gains if the positive momentum continues.

TVTX’s Bullish Momentum Intact—Position for FDA Decision and 42.13 Resistance
Travere Therapeutics’ 13.91% surge is a testament to the stock’s ability to harness regulatory optimism and strong fundamentals. With the FDA’s PDUFA date for Filspari on January 13, 2026, and the stock trading near its 52-week high of $42.13, the near-term outlook remains bullish. Investors should monitor the 42.13 level as a critical resistance and the 200-day moving average at $22.086 as a key support. The sector leader, Amgen (AMGN), is up 0.745% intraday, underscoring the biotech sector’s mixed performance. For TVTX, the path forward hinges on maintaining momentum above $40.28 and securing a favorable FDA decision. Aggressive bulls may consider TVTX20260116C42.5 into a breakout above $42.13.